Impact of low-level pretransplant donor-specific antibodies detected by the Luminex platform on acute rejection and long-term graft survival

Table 1 Demographic and clinical parameters of the study population

Parameter	n = 78
Age of recipients (years)	29.57 ± 10.11
Recipient gender
Males	49 (62.8)
Females	29 (37.2)
Age of donors (years)	34.53 ± 9.09
Donor gender
Males	46 (59.0)
Females	32 (51.0)
Donor relation
Siblings	46 (58.9)
Parents	14 (17.9)
Spouses	17 (21.8)
Offspring	1 (1.3)
HLA mismatches
1-2	21 (27.0)
3-4	37 (47.4)
5-6	20 (25.6)
Duration of hemodialysis (months)	14.01 ± 15.48
End-stage kidney disease cause
Unknown	48 (61.5)
Chronic glomerulonephritis	20 (25.6)
Stone disease	5 (6.4)
Bladder outlet obstruction and neurogenic bladder	3 (3.8)

Data are presented as n (%) or mean ± SD. HLA: Human leucocyte antigen.